We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Solid Tumor Marker Diagnostic Test Receives CE Certification

By LabMedica International staff writers
Posted on 26 Sep 2013
A CE-certified in vitro diagnostic test is now available for the semi-quantitative determination of the tumor marker Claudin-18.2 (CLDN18.2).

The test called CLAUDETECT 18.2, was developed jointly by Ganymed Pharmaceuticals (Mainz, Germany) and Theracode GmbH (Mainz, Germany), and will be marketed by Ganymed.

Ganymed Pharmaceuticals AG is a biopharmaceutical company that has developed a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). More...
IMABs are unique in that they are highly selective for proteins present on tumor cells, but do not bind to healthy cells. Theracode GmbH is an in vitro diagnostics company that combines its in-house scientific and management expertise in immunology, molecular pathology, and clinical medicine with its own integrated discovery and development platform to identify, validate, develop, manufacture, and market in vitro diagnostic kits based upon new classes of highly sensitive and cancer specific molecular markers.

CLAUDETECT 18.2 is a semi-quantitative immunohistochemical assay that determines selectively CLDN18.2 protein expression in formalin fixed paraffin-embedded (FFPE) cancer tissues. The tight junction protein Claudin-18.2 is expressed in up to 80% of gastroesophageal adenocarcinomas, 60% of pancreatic tumors as well as in other various solid tumors. CLDN18.2 is the target of the therapeutic antibody IMAB362, Ganymed’s lead investigational drug product.

The CLAUDETECT 18.2 test has been certified to comply with the requirements of European Community Directive 98/79/EC on in vitro diagnostic medical devices for use in diagnosing patients with adenocarcinoma of the stomach, esophagus, and pancreas as well as bile duct and lung.

“Ganymed is dedicated to develop predictive biomarkers that complement new therapeutic concepts in cancer treatment and hold promise for personalizing medicine,” said Dr. Özlem Türeci, CEO of Ganymed Pharmaceuticals. “With the CE marking of CLAUDETECT 18.2, we have achieved an important milestone in the concurrent development of our drug IMAB362 and the diagnostic tool intended to aid in the identification of patients for treatment with IMAB362.”

Related Links:
Ganymed Pharmaceuticals
Theracode GmbH



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Urinalysis Solution
UN-9000
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.